- Additional Pipeline Product Agreement Executed to Support ConjuChem's R&D Efforts -
MONTREAL and BAGSVAERD, Denmark, Dec. 3 /PRNewswire-FirstCall/ - ConjuChem Biotechnologies Inc. (TSX:CJB) and Novozymes Biopharma UK Ltd., a subsidiary of Novozymes A/S (LSE:NVZ) announced today that the Companies have entered into a long-term Manufacturing and Supply Agreement by which Novozymes Biopharma will exclusively supply its recombinant human albumin, Recombumin(R), for the continued development and commercialization of ConjuChem's PC-DAC(TM):Exendin-4. The Agreement calls for the initiation of additional capacity expansion of Novozymes Biopharma's Nottingham, England facility as well as additional expansion as global demand for PC-DAC(TM):Exendin-4 increases. The Agreement also allows ConjuChem to fully assign all rights to a PC-DAC(TM):Exendin-4 licensee.
In a separate Agreement, ConjuChem and Novozymes Biopharma entered into a Pipeline Product Agreement by which Novozymes Biopharma will also supply Recombumin(R) or other recombinant albumin products for the further development of ConjuChem's research and development product candidates.
Commenting on the Agreements, Mark Perrin, President & CEO of ConjuChem stated, "Recombumin(R) is an important part of our current technology and Novozymes Biopharma has been an integral partner in the development of our peptide conjugation platform. These two Agreements further solidify our relationship and are validation of the promise of our technology."
Peter Rosholm, Vice President of Novozymes Biopharma added, "This agreement allows Novozymes to demonstrate its commitment and capability to supply quality materials for use in biopharmaceutical manufacture and appropriate regulatory support on a long-term basis and thereby position itself as a reliable partner in this market."
|SOURCE ConjuChem Biotechnologies Inc.|
Copyright©2008 PR Newswire.
All rights reserved